NO326689B1 - Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene - Google Patents

Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene

Info

Publication number
NO326689B1
NO326689B1 NO20035440A NO20035440A NO326689B1 NO 326689 B1 NO326689 B1 NO 326689B1 NO 20035440 A NO20035440 A NO 20035440A NO 20035440 A NO20035440 A NO 20035440A NO 326689 B1 NO326689 B1 NO 326689B1
Authority
NO
Norway
Prior art keywords
compounds
preparation
pharmaceutical composition
pyrrolidine derivatives
pyrrolidine
Prior art date
Application number
NO20035440A
Other languages
English (en)
Other versions
NO20035440D0 (no
Inventor
Gita Punjabhai Shah
Chuen Chan
Robert John Young
Henry Anderson Kelly
Andrew Mcmurtrie Mason
Vipulkumar Kantibhai Patel
Julie Nicole Hamblin
Nigel Paul King
Stefan Senger
Nigel Stephen Watson
Helen Elisabeth Weston
Caroline Whitworth
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20035440D0 publication Critical patent/NO20035440D0/no
Publication of NO326689B1 publication Critical patent/NO326689B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
NO20035440A 2001-06-08 2003-12-05 Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene NO326689B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114005.2A GB0114005D0 (en) 2001-06-08 2001-06-08 Chemical compounds
PCT/GB2002/002721 WO2002100830A1 (en) 2001-06-08 2002-06-06 Pyrrolidine derivatives as factor xa inhibitors

Publications (2)

Publication Number Publication Date
NO20035440D0 NO20035440D0 (no) 2003-12-05
NO326689B1 true NO326689B1 (no) 2009-01-26

Family

ID=9916209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035440A NO326689B1 (no) 2001-06-08 2003-12-05 Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene

Country Status (29)

Country Link
US (4) US7186717B2 (no)
EP (1) EP1395553B1 (no)
JP (1) JP4242274B2 (no)
KR (1) KR100877245B1 (no)
CN (1) CN1256324C (no)
AR (1) AR036086A1 (no)
AT (1) ATE289294T1 (no)
AU (1) AU2002311451B2 (no)
BR (1) BR0210207A (no)
CA (1) CA2449629A1 (no)
CO (1) CO5540285A2 (no)
CZ (1) CZ20033325A3 (no)
DE (1) DE60203006T2 (no)
DK (1) DK1395553T3 (no)
ES (1) ES2235050T3 (no)
GB (1) GB0114005D0 (no)
HK (1) HK1063471A1 (no)
HU (1) HUP0400156A3 (no)
IL (1) IL159195A0 (no)
MX (1) MXPA03011384A (no)
MY (1) MY136859A (no)
NO (1) NO326689B1 (no)
NZ (1) NZ530004A (no)
PL (1) PL368082A1 (no)
PT (1) PT1395553E (no)
SI (1) SI1395553T1 (no)
TW (1) TWI298719B (no)
WO (1) WO2002100830A1 (no)
ZA (1) ZA200309367B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
ATE533491T1 (de) 2004-09-21 2011-12-15 Trobio Ab Stabilisierte protease zusammensetzungen enthaltend eine serinprotease, morpholin-derivate und reversible serinprotease- inhibitoren
WO2006047415A2 (en) * 2004-10-26 2006-05-04 Janssen Pharmaceutica, N.V. Factor xa compounds
WO2006110726A2 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited Dosage formulations and methods of treatment and prevention
CN102380100A (zh) * 2005-09-22 2012-03-21 特罗比奥股份公司 稳定的蛋白酶组合物
JP5080476B2 (ja) * 2005-09-22 2012-11-21 トルービオ・アーベー 安定化プロテアーゼ組成物
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
SI2989095T1 (sl) * 2013-04-26 2019-03-29 Sanofi Tartratna sol 5-kloro-tiopen-2-karboksilne kisline((s)-2-(metil-3-(2-okso-pirolidin-1-il)-benzensulfonilamino)-3- (4-metil piperazin-1 il)-3-okso-propril)amida
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4121947A1 (de) * 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) * 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
JP2001504810A (ja) 1996-10-11 2001-04-10 シーオーアール・セラピューティックス・インコーポレーテッド 選択的第Ｘａ因子阻害剤
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
KR20000057528A (ko) 1996-12-13 2000-09-25 오흘러 로스 제이. 설폰산 또는 설포닐아미노 ｎ-(헤테로아르알킬)-아자헤테로사이클릴아미드 화합물
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
AU9280698A (en) * 1997-09-30 1999-04-23 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
UA59433C2 (uk) 1998-01-27 2003-09-15 Авентіс Фармасьютікалс Продактс Інк. ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ
US6281277B1 (en) 1998-04-22 2001-08-28 Showa Denko Kabushiki Kaisha Homogeneously surface-fluorinated metal oxide particulates, process for manufacturing the same, and use of the same
ATE233259T1 (de) 1998-12-31 2003-03-15 Aventis Pharma Inc 3-(thio-substituierte amido)-lactame, verwendbar als inhibitoren der matrix-metalloproteinase
EP1175405A4 (en) 1999-02-09 2002-05-15 Bristol Myers Squibb Co LACTAM INHIBITORS OF FACTOR Xa AND ASSOCIATED METHOD
AU3192500A (en) * 1999-03-16 2000-10-04 C & C Research Laboratories Substituted proline derivatives and medicinal compositions containing the same
WO2000069465A1 (fr) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Agents anticancereux contenant des antagonistes de ep1 en tant que principe actif
ATE423113T1 (de) 1999-07-28 2009-03-15 Aventis Pharma Inc Substituierte oxoazaheterozyclische verbindungen
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form

Also Published As

Publication number Publication date
US7517879B2 (en) 2009-04-14
NZ530004A (en) 2005-08-26
EP1395553A1 (en) 2004-03-10
US20050107379A1 (en) 2005-05-19
KR100877245B1 (ko) 2009-01-07
MXPA03011384A (es) 2004-04-05
ATE289294T1 (de) 2005-03-15
DK1395553T3 (da) 2005-06-06
CA2449629A1 (en) 2002-12-19
ES2235050T3 (es) 2005-07-01
HUP0400156A2 (hu) 2004-07-28
MY136859A (en) 2008-11-28
CN1256324C (zh) 2006-05-17
WO2002100830A1 (en) 2002-12-19
PT1395553E (pt) 2005-06-30
HK1063471A1 (en) 2004-12-31
US20070155745A1 (en) 2007-07-05
US7186717B2 (en) 2007-03-06
KR20040004706A (ko) 2004-01-13
DE60203006T2 (de) 2006-03-30
PL368082A1 (en) 2005-03-21
BR0210207A (pt) 2004-08-03
CN1538955A (zh) 2004-10-20
JP4242274B2 (ja) 2009-03-25
US7429587B2 (en) 2008-09-30
JP2004537530A (ja) 2004-12-16
AR036086A1 (es) 2004-08-11
NO20035440D0 (no) 2003-12-05
US20070142375A1 (en) 2007-06-21
ZA200309367B (en) 2004-08-02
TWI298719B (en) 2008-07-11
CO5540285A2 (es) 2005-07-29
EP1395553B1 (en) 2005-02-16
DE60203006D1 (de) 2005-03-24
AU2002311451B2 (en) 2006-03-02
GB0114005D0 (en) 2001-08-01
HUP0400156A3 (en) 2008-10-28
US20070142374A1 (en) 2007-06-21
US7326785B2 (en) 2008-02-05
SI1395553T1 (en) 2005-06-30
CZ20033325A3 (cs) 2004-08-18
IL159195A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
NO329884B1 (no) Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
LTPA2014005I1 (lt) Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
NO20041879D0 (no) Polymorf form av rimonabant, fremgangsmate for fremstilling derav og farmasoytisk preparat inneholdende det samme.
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NO20016038L (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
NO20034864D0 (no) Preparat for behandling av legemiddelindusert forstoppelse med 15-keto-prostaglandiner
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
PL347105A1 (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
NO20042640L (no) Fremgangsmate for fremstilling av ekinocandinderivater
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
NO20035586L (no) Fremgangsmate for fremstilling av cykloheksanol-derivater
NO20031108D0 (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
EP1556364A4 (en) ISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES
NO20032297L (no) Fremgangsmåte for fremstilling av distamycinderivater

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees